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T HE ESSENTIAL ingredients for the 
transplantation of any organ include 
perfection of surgical techniques, adequate 
organ procurement and preservation, develop-
ment of methods to prevent rejection, and 
definition of the role of tissue matching. This 
framework for practical application was 
worked out almost exclusively with the simple 
kidney model, and then applied with certain 
modifications to the transplantation of the 
extrarenal organs. Consequently, it is no sur-
prise that almost all of the contributors to the 
transplantation of extrarenal organs have had 
a background in the renal field, and fre-
quently have made significant contributions 
to surgical nephrology. 
A marriage of interests is obvious in the 
development of liver transplantation. The first 
descriptions of liver replacement in experi-
mental animals were published less than 25 
years ago,I,2 from groups with an interest-
then and subsequently-in renal transplanta~ 
tion. The first clinical effort at liver transplan-
tation was made on March 1, 1963,3 by a 
group devoted to the development of renal 
transplantation. Activities in liver transplan-
tation continued at a very modest level for the 
next 16 years, largely because the succeses 
rate was so small. The great wave of human 
liver transplantations worldwide began in the 
early 1980s, following the introduction of the 
new immunosuppressive agent, cyclosporine, 
by the kidney transplanter, Roy Caine of 
Cambridge, England. In the following sec-
tions, the influence of cyclosporine, as well as 
other factors which made liver transplantation 
practical, will be described. 
IMMUNOSUPPRESSION 
More than 20 years ago, the possibility of 
obtaining long-term survival after liver trans-
plantation was demonstrated in mongrel dogs 
treated with azathioprine.4 Although only 
about 10% of the animals achieved survival 
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for more than four postoperative months, 
many of these dogs lived for long periodss and 
one survived for a full canine lifetime. Similar 
results were obtained shortly afterward with 
heterologous antilymphocyte serum (ALS) 
and its globulin derivative (ALG).6 
Although liver replacement in humans was 
first attempted in 1963, the first clinical trials 
all failed and extended survival was not 
accomplished until the summer of 1967.7 The 
first successfully treated patient eventually 
died of metastases from the hepatoma for 
which treatment was provided. The longest 
survivor in the world today is a young woman 
who was treated in Jan 1970 for biliary atre-
sia. It is interesting that her excised liver 
contained an incidental hepatoma which 
obviously was completely eliminated/ allow-
ing a cure. Immunosuppression was with aza-
thioprine, prednisone, and ALG. 
Clinical Immunosuppressive Regimens 
Before Cyclosporine 
Development with rB.nal transplanta-
tion. The first step in pharmacologic immu-
nosuppression was the use of azathioprine as 
the sole or principal immunosuppressive agent 
in the Boston trials of 1962.8•9 There were no 
long-term survivors, and since that time, it has 
been recognized that cadaver organ trans-
plantation could rarely, if ever, be successful 
using azathioprine alone. 
The so-called modern era of whole organ 
transplantation began in 1962 and 1963 with 
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the demonstration that azathioprine and ste-
roids had at least additive, if not synergistic, 
actions. lO The introduction of this so-called 
double-drug therapylO was quickly adopted in 
other centers,11,12 and large numbers of 
patients began to emerge from renal trans-
plantation clinics with chronically functioning 
grafts. 13 However, satisfactory results were 
obtained for many years only with living 
related donors, and the mortality and morbid-
ity from the transplantation of cadaver kid-
neys kept case accrual at a relatively low 
level. 14 
The number of modifications of the original 
double-drug therapy in the succeeding years 
was large (Table 1), the most important 
change being the addition of ALG as a third 
and short-term immunosuppressive ad-
junct.6,22 Most centers in which this expedient 
was tried reported improved results, but the 
use of ALG was limited by the inability to 
standardize the agent and by its undesirable 
side effects.5•22 A new era of ALG therapy has 
been made possible with the development of 
monoclonal antibody techniques, pioneered by 
Kohler and Milstein.23 Using potent and 
highly standardized antilymphoid monoclonal 
antibodies, Cosimi et aj21 and others24.25 have 
shown regular reversal of otherwise intracta-
ble rejections. 
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Other variations in immunosuppression 
between 1962 and 1979 are summarized in 
Table I, including the substitution of cyclo-
phosphamide for azathioprine,16 and the use 
of thoracic duct drainagel5,26 or total lymphoid 
irradiation l7•18 as an alternative to ALG for 
lymphoid depletion. None of these techniques 
has had a major impact on clinical transplan-
tation. 
App/i cat ion to liver transpl anta-
lion. From 1963 through 1969, most of our 
liver recipients had triple-drug immunosup-
pression with azathioprine, prednisone, and 
ALG. In some, cyclophosphamide was substi-
tuted for azathioprine, and in a few others, 
lymphoid depletion was achieved with tho-
racic duct drainage instead of ALG. Details of 
these variations are summarized elsewhere. 27 
The failure of any of the variations to 
influence survival after liver transplantation is 
evident in Fig 1. 
The Impact of Cyclosporine 
The experimental studies of Borel et aj28 
and the first clinical trials by Caine et al 19 of 
cyclosporine A opened a new era in transplan-
tation. 
Development with renal transplanta-
tion. The most important encouraging ob-
servation by CaIne et al 19 was that almost half 
Table 1. Immunosuppressive Drug Regimens and Adjuncts for Kidney Transplantation and Applied later for 
Agents 
Azathioprine 
Azathioprine-steroids 
Thoracic duct drainage as adjunct 
ALG as adjunct 
Cyclophosphamide substitute for 
azathioprine 
Total lymphoid irradiation 
Cyciosporine alone 
Cyciosporine-steroids 
Monoclonal ALG as adjunct 
Extrarenal Organs 
Year Described 
and Reported Place 
19628 .• Boston 
1963' Denver 
1963'0* Stockholm 
19666 Denver 
1970'· Denver 
1979"·'8 Palo Alto, Minn 
1978- Cambridge 
1979" 
198020 Denver 
1981 21 Boston 
Used 
Deficiencies for Livers 
Ineffective, dangerous No 
Suboptimal Yes 
Nuisance: requires 20-30 d pre- Yes 
treatment 
Suboptimal Yes 
No advantage except for patients Yes 
with azathioprine toxicity 
Dangerous; extensive preparation; Yes 
not quickly reversible 
Suboptimal Yes 
Under evaluation Yes 
Under evaluation Yes 
*It was not realized until much later that pretreatment for three to four weeks before transplantation was a necessary 
condition. 15 
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Fig 1. Results obtained over a 16-year period using 
the conventional immunosuppression shown in Table 1. 
Note the failure to improve the results despite the 
acquisition of considerable experience. 
of their whole organ recipicnts had achieved 
chronic graft function with no other agent 
than cyclosporine. However, the development 
of lymphomas in nearly 10% of their recip-
ients, the fact that nonc of the kidney recip-
ients achieved normal graft function, and a 
high patient mortality rate militated against 
the wide use of cyclosporine until these 
adverse findings had been explained or mini-
mized in subsequent trials. 
The lymphoma question was resolved with 
incrcased information about thc etiology and 
appropria te treatment of these lesions. The 
lymphomas were provcd to be complications 
of primary or secondary infection with 
Epstein-Barr virus20,29 and it was learned that 
the lesions would undergo spontaneous resolu-
tion with discontinuance or even reduction of 
the immunosuppressive doses. 3D This involu-
tion occurred whether the lesions were poly-
clonal or monoclonal, overthrowing a previous 
hypothesis of the effect of monoclonality that 
almost had become dogma. 29 
The development of de novo malignancies 
in immunosuppressed patients has not been 
unique to cyclosporine. Since the late 
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1960s/1,32 an association of epithelial cancers 
with conventional immunosuppression has 
been well known, the epithelial lesions out-
numbering the lymphomas by a ratio of about 
4:1.33 Fortunately, there has been little or no 
increase in the incidence of epithelial tumors 
using cyclosporine-steroid therapy. Thus, the 
risk of the development of malignancies is 
probably less overall with cyclosporine--ste-
roid thcrapy than with azathioprine and pred-
nisone (with or without ALG), even if one 
considers the lymphomas to be true tumors, a 
concession that has been challenged. 34 
Understanding of the effects of cyclospo-
rine on renal function has been central to the 
effective use of cyclosporine. The fact that the 
agent is nephrotoxic was first reported by 
Caine et aJ1 9 and confirmed in many subse-
quent reports including our own. 20,35,36 With 
the nephrotoxic problem, the full exploitation 
of the drug was not possible without com-
bining it with other agents, of which predni-
sone was most important.20,36 By so doing, it 
was possible to minimize the contribution of 
homograft rejection to poor renal function 
while at the same time ameliorating the neph-
rotoxicity by reducing the requisite doses of 
cyclosporine. Othcr drugs have bcen proposed 
and/or tried in modifications of the pharma-
cologic cocktail concept,37,38 always using the 
cyclosporine-steroid combination as the base-
line. Normal renal transplant function has 
become the rule. We have recently used the 
OKT3 antibody originally tested by Cosimi et 
al in patients who developed intractible rejec-
tion in spite of cyclosporine-steroid therapy, 
and with a high incidence of reversal. 
The high mortality rate with the first use of 
cyclosporine apparently was a reflection of a 
learning experience in which drug overdosage 
was common. Even in our first trials with the 
far safer cyclosporine-steroid combination, 
the one-year mortality rate after cadaveric 
renal transplantation was 13.6%,39 but in the 
following year, thc one-year mortality rate 
was reduced to 2%.40 Since then, most groups 
using cyclosporine-steroid therapy have had a 
mortality rate of <5%. 
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Application to liver transplantation. The 
systematic use of cyclosporine-steroid ther-
apy in liver transplantation was begun in early 
1980.41 Almost immediately, a doubling of 
one-year patient survival was noted. Each 
subsequent year, the case load in our center 
has increased until the calendar year of 1984, 
when 166 liver replacements were performed 
at the University of Pittsburgh. Augmented 
activity in other centers throughout the world 
has been documented.42 
It was surprising in the early trials of 
cyclosporine-steroid therapy that such good 
kidney or liver graft survival could be 
achieved without knowing what the cyclospo-
rine blood levels actually were. The clinical 
judgment in managing such patients reflected 
a deliberate effort to balance the possibilities 
of rejection against those of nephrotoxicit/6 
and to treat both. 
Nowadays, the assessment of whole blood 
or plasma cyclosporine concentration is possi-
ble with radioimmunoassay (RIA) or high-
performance liquid chromatography (HPLC). 
Heavy reliance is now placed on the results of 
these tests for management decisions. This 
has been a particularly important develop-
ment in liver recipients, since the intestinal 
absorption of cyclosporine postoperatively has 
been unpredictable and to some extent depen-
dent on the quality of graft function. To 
smooth out the recovery period and to assure 
continuity of therapeutic levels of the drug, 
cyclosporine has been administered both 
intravenously and orally for several days, 
weeks, or even months postoperatively.42 As 
absorption improves with the oral drug, the 
intravenous doses are weaned and eventually 
discontinued. 
From our first efforts in 1963 through 
1979, 170 patients were treated with conven-
tional immunosuppression. The chances for 
living one year after liver replacement were 
only about one in three (Fig 2). Subsequently, 
244 liver recipients were provided with cyclos-
porine-steroid therapy between March 1980 
and July 1, 1984, allowing follow-up periods 
of one to more than five years. The chances of 
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Fig 2. Marked improvement in results of liver trans-
plantation after the introduction to cyclosporine-
steroid therapy in early 1980. 
one-year survival were more than doubled. 
Actuarial projections beyond one year indi-
cate that these gains will be sustained for at 
least one-half decade (Fig 2). 
Certain risk factors have been carefully 
looked at for their effect on survival curves. 
Among the more important has been age. 
Pediatric recipients throughout the entire his-
tory of liver transplantation have fared better 
by ten to 25 percentage points than adults, 
and in the cyclosporine era, the age factor has 
been particularly important (Fig 3). 
Somewhat surprisingly, specific diseases 
that have destroyed the native liver have not, 
for the most part, influenced survival. In 
adults, for example, the outcome has been 
about the same with such diverse diseases as 
primary biliary cirrhosis, sclerosing cholangi-
tis, and inborn errors of metabolism. Two 
high-risk diseases have been identified so far. 
The results with postnecrotic cirrhosis and 
with primary hepatic tumors have been infe-
rior. With cirrhosis, the principal explanations 
have been the technical difficulties of the 
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Fig 3. Comparison of results in adult and pediatric 
recipients during the cyclosporine era of 1980 through 
1984. 
operation caused by the pathologic process, 
the generally poor condition of the cirrhotic 
patient, and the almost universal recapitula-
tion of their original chronic active hepatitis in 
B-virus carriers. 
In patients whose reason for liver replace-
ment was primary hepatic malignancy that 
could not be removed by conventional subtotal 
hepatic resection, the early mortality rate has 
been quite low with >80% of the recipients 
alive at six months. A steady decline thereaf-
ter has been caused by recurrent tumor, which 
can be expected in 80% or more of patients 
who live long enough for metastases to be 
detected. The only acceptable results thus far 
have been in patients with the slow-growing 
and nonaggressive fibrolamellar hepatomas, 
which recently have been recognized to be a 
favorable variant within the larger hepatoma 
category.43,44 
In children, the results have been about the 
same in all of the main disease categories. It 
has been interesting that the survival in chil-
dren with biliary atresia has been competitive 
with that obtained with other diseases. Trans-
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Fig 4. The lack of influence of underlying disease on 
the survival of children undergoing liver transplanta-
tion. 
plantation is technically much more difficult 
in children previously submitted to Kasai 
operations and re-explorations, but there has 
not been a demonstrable penalty in terms of 
either early or late survival (Fig 4). 
More complete accounts of underlying dis-
ease and other risk factors are being published 
everywhere.4S,46 The improved survival that 
has been achieved in recent years has been 
made possible, in part, by an aggressive use of 
retransplantation to rescue patients whose 
first grafts have failed because of rejection or 
for any other reason. Retransplantation was 
not a successful enterprise under conventional 
immunosuppression,27 but in the modern 
times defined by the availability of cyclospo-
rine, the picture has drastically changed.47 
THE ROLE OF TECHNICAL IMPROVEMENTS 
WITH SPECIAL REFERENCE TO 
VENOVENOUS BYPASSES 
The technical principles of liver transplan-
tation have been well established for almost 
two decades/'s but until the 1980s, the most 
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significant development was standardization 
of biliary tract reconstruction. 27 .48 More 
recently, pump-driven venovenous bypasses 
have been introduced clinically, and in the 
following account, the influence of the 
bypasses on the actual operation will be 
described. 
When the technique of liver transplantation 
was developed in dogs,l,2 operative survival 
required venovenous bypasses that transmit-
ted blood from the inferior vena cava and the 
portal vein to the upper part of the body while 
the venous systems were obstructed during the 
anhepatic phase of the procedure. Without 
bypasses, the capillary beds were ruined in 
dogs by acute venous hypertension even with 
occlusion times as short as 30 minutes. The 
original bypasses were used without heparini-
zation or pumps. 
From the first experience with liver trans-
plantation in humans, it was concluded that 
venovenous bypasses were not obligatory for 
survival. Because the bypass tubing was the 
source of intraoperative pulmonary emboli in 
at least three patients,5 passive venovenous 
bypasses were virtually abandoned. Pump-
driven venovenous27,49 or venoarterial50 by-
passes under systemic heparinization were 
impractical because reversal of the heparin 
effect was often difficult or impossible in the 
presence of multiple other coagulation defects 
caused by liver disease. 
Without provision to decompress the 
obstructed splanchnic and systemic venous 
beds, every liver replacement in patients was 
carried out in a crisis atmosphere comparable 
to that with open cardiac surgery under inflow 
occlusion. When time was such a precious 
commodity, efforts were made to mobilize the 
diseased liver as completely as possible before 
venous occlusion. Even so, hemostasis in the 
bare areas that were opened up during the 
final stages of hepatectomy usually had to be 
put off. Augmented hemorrhage from these 
bare areas was one of the most troublesome 
problems caused by venous occlusion. High-
pressure bleeding from the thin-walled collat-
era Is in the raw surfaces of the operative 
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wound often could not be controlled by any 
mechanical means until the obstructed venous 
systems could be decompressed by revascular-
izing the new liver. 
In 1982 and 1983, a pump-driven venove-
nous bypass system without recipient heparin-
ization was developed, tested in dogs,51 and 
eventually brought to the clinical operating 
rooms.52.53 Then it became possible to modify 
and improve several aspects of the recipient 
operation, including the technique of hepatec-
tomy. 
Preliminary Steps 
The principles of recIpient hepatectomy 
have been thoroughly described.5.54 However, 
the extent of preliminary dissection can be 
greatly decreased if venovenous bypass is to be 
used. The individual structures of the hepatic 
hilum usually are skeletonized, but no other 
areas need to be invaded. Specifically, efforts 
to mobilize the liver from the hepatic fossa 
usually are deferred. 
In patients whose hepatic hilum has been 
dissected before, it may be easiest to approach 
the hilar structures from the left side. Even 
when scarring is extreme, the lesser omental 
sac can be entered if the left triangular liga-
ment is incised and the lateral segment of the 
liver is retracted into the wound. By following 
the lesser sac toward the hilum, the proper 
plane can be assured. 
When the bypass is ready for implementa-
tion, the hepatic artery and the common duct 
are ligated and divided (Fig 5, upper portion). 
The portal vein cannula for the venovenous 
bypass is inserted as well as the femoral 
cannula, allowing both the splanchnic and 
systemic systems to be brought into the pump-
driven venovenous circuit that is usually 
directed into the axillary vein (Fig 5, upper 
portion). In adults, 1 to 6 L of blood per 
minute are bypassed. With bypass, simulta-
neous obstruction of the portal vein and infe-
rior vena cava causes little change in blood 
pressure, cardiac output or other measures of 
cardiopulmonary function. 53 The operative 
field is tranquil. 
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Fig 5. (Upper) Cannulas inserted for decompression of the inferior vena cava (lVC) and portal venous (PV) 
systems. The blood is usually pumped back into the axillary vein. (Lower) Technique of removing the liver by peeling 
it out from below upward. Abbreviations: HA. hepatic artery; CD. common duct. 
The Hepatectomy 
On venovenous bypass, the right hepatic 
lobe can be retracted into the wound (Fig 5, 
lower portion, and Fig 6). If it has been 
difficult to encircle the inferior vena cava, this 
can now be done either just below or above the 
liver, and eventually at both locations. 
Once the venovenous bypass is started, all 
of the structures that are still holding the liver, 
including the infrahepatic vena cava, can be 
divided (Fig 5, lower portion). The triangular 
ligaments are cut if these have not been 
incised already, as well as the leaves of perito-
neal reflection which make up the coronary 
ligament (Fig 6). The bare areas are entered 
on both the right and left sides (Fig 6). As 
described before,54 the liver can then be 
shelled out on the stalk formed by the supra-
hepatic vena cava connection (Fig 6A). The 
vena caval cuff for eventual anastomosis can 
be developed (Fig 68). 
Once the liver has been taken out, it is 
possible while using venovenous bypass to 
close all of the raw surfaces that were created 
during the hepatectomy. This is usually done 
with a continuous monofilament poly pro po-
lene (Prolene) suture, beginning at the tip of 
the right triangular ligament and continuing 
this centrally in rows that eventually are con-
nected (Fig 7-1). The superior leaf of the 
coronary ligament can be the starting point, 
with continuation into the bare area itself (Fig 
7-2) and finally to the inferior portion of the 
coronary ligament. When these continuous 
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Fig 6. (A) Continuation of the maneuver by which 
the liver is peeled out of the hepatic fossa from below 
upward. (B) The suprehepatic vena cava has been 
crossclamped and the liver is dissected away from the 
vena cava in order to increase the length of the cuff. 
510;/ of the 
final row 
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suture lines are eventually incorporated into a 
single suture line, all of the right bare area is 
eliminated (Fig 7-3). The same principle is 
followed in dealing with the left triangular 
and falciform ligaments (Fig 7-4) 
Of vital importance is the bare area behind 
the excised recipient inferior vena cava, where 
the right adrenal gland is left behind (Fig 
7-1). This region is sewed in a superior-
inferior orientation and as the continuous 
suture is placed, an effort is made to place at 
least a double layer by sewing first down and 
then up (Fig 7-5). By the time this final suture 
line has been completed, virtually all of the 
bare areas have been eliminated. The time 
necessary for these hemostatic maneuvers is 
30 to 90 minutes. The investment is rewarded 
later when, if major hemorrhage occurs from 
the hepatic fossa after the new liver is revascu-
larized, it can be assumed with some degree of 
assurance that the bleeding is from the graft 
itself or from one of the anastomoses rather 
than from raw recipient tissues. 
Alternative Approaches 
There is no single best way to remove a 
disease native liver. At the beginning of the 
operation, and after exposure has been 
obtained, it is important to assess the situa-
tion, to decide upon whatever technical 
approach the basic pathology will permit, and 
to determine if the operation just described 
needs to be modified. It may be impossible in 
some patients because of scarring or massive 
formation of variceal collaterals to individu-
ally dissect the structures of the portal triad. 
If so, a vascular clamp can be placed across all 
of the portal triad structures, which are trans-
ected simultaneously (Fig 8). The portal vein 
can be dissected free for cannulation, and the 
other triad structures are dissected back. If 
the portal vein contains new or old thrombus, 
the placement of a portal cannula could be 
dangerous, and only the vena cava should be 
bypassed. 
In a few patients, encirclement of the vena 
cava below the liver at an early stage of the 
operation may be difficult or impossible, 
I 
I 
Portal 
vein 
I 
Hepatic 
artery 
115 
Fig 8. Mass clamping of the portal structures. The 
maneuver is indicated if there is great difficulty in 
individually dissecting the structures of the triad. These 
structures can then be dissected back from the cut 
ends. 
whereas encirclement of the suprahepatic 
vena cava can be easy. We have then cross-
clamped the suprahepatic vena cava, boldly 
cut across it, and stripped the liver out from 
above downward (Fig 9). Fatal hemorrhage is 
prevented with occluding fingers thrust down 
the vena cava (Fig 9). The vena cava below 
the liver is clamped and transected as the final 
step. 
Vascular Anastomotic Cuffs 
With the relative leisure provided by the 
venous bypass, good venous cuffs can be fash-
ioned after the liver is out. If the cuffs are 
adequate, the anastomoses of the vena cava 
above and below the liver are easy to construct 
in the quiet operative field that exists under 
venovenous bypass. During performance of 
the lower vena caval anastomosis, the liver is 
flushed with cold lactated Ringer's or saline 
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Fig 9. Removal of the liver from above downward. 
with prevention of hemorrhage by 'Iingers thrust down 
the lumen of the vena cava. The maneuver may be 
indicated if it is difficult or impossible to safely encircle 
the inferior vena cava below the liver. 
solution to remove entrapped air from the 
major veins and to rid the graft of the high 
potassium solution used for preservation.55 
The portal bypass cannula is now clamped, 
leaving the patient on vena caval venous 
bypass during construction of the portal ana-
stomosis; then the first three anastomoses are 
released. The liver is now revascularized with 
portal blood. The bypass is discontinued and 
all bypass cannulas are removed. After rea-
sonable hemostasis is obtained, the liver is 
arterialized by previously described tech-
niques5.56.57 and the biliary tract is recon-
structed with choledochocholedochostomy or 
Roux-en-Y choledochojejunostomy.27 There 
may be an occasional reason to perform all 
four vascular anastomoses before restoring 
blood flow to the liver, but the potential 
advantage of complete revascularization at 
one time is usually outweighed by the even 
grea ter desirability of early restoration of 
portal flow. 
Bypasses for Children 
Venovenous bypasses have been routinely 
used only for recipients of adult size. Infants 
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and small children tolerate occlusion of the 
portal vein and inferior vena cava reasonably 
well. Nevertheless, low-flow bypasses are 
being used with increasing frequency in pedi-
atric recipients,58 as it has been realized that 
bypasses with low flows can be conducted with 
safety. 
Simplication of Bypass Techniques 
The low-flow atraumatic centrifugal pump 
has proved to be the most important ingre-
dient of the bypass system, as emphasized in 
the original canine studies of Denmark et al. 51 
The later addition, for safety purposes, of 
more expensive heparin-bonded (Gott) cannu-
las and tubing52.53 may not be necessary, even 
for the low-flow bypasses used in pediatric 
recipients. 58 Research on the issue of the hepa-
rin-bonded extra corporeal equipment is going 
on in our laboratories and elsewhere. 
THE ROLE OF TISSUE MATCHING 
In patients treated with cyclosporine and 
steroids after renal transplantation, the anti-
gen matching at the A, B, or D loci has had 
little influence on the results. Such matching 
has not even been attempted for liver recip-
ients. Tissue matching will playa significant 
role in further developments in liver trans-
plantation. 
The remarkable resistance of the liver to 
hyperacute rejection has been reported 
before.59,6o There has been no obvious penalty 
with transplantation of livers to recipients 
whose sera contain the cytotoxic anti-graft 
antibodies that almost invariably lead to 
immediate loss of kidney grafts. Furthermore, 
many liver transplantations have been and are 
being carried out across the ABO blood group 
barriers that frequently (although not invari-
ably) cause hyperacute rejection of kidneys as 
the consequence of anti-graft isoagglutinins. 13 
Recognition that matching is nonrelevant in 
liver transplants has simplified some of the 
logistic problems of liver transplantation. 
ORGAN REMOVAL AND PRESERVATION 
Great advances have been made in multiple 
organ removal, and a relatively standard pro-
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Fig 10. In situ infusion technique used when the kidneys and liver are removed from the same donor. 
Abbreviations: R.g.a., right gastric artery; G.d.a., gastroduodenal artery; S.a., splenic artery; S.v .. splenic vein; P.v .. 
portal vein; and S.m.v., superior mesenteric vein. Reproduced by permission." 
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cedure is being used throughout most of the 
United States. 61 The operation is done 
through a complete midline incision from the 
suprasternal notch to the pubis, including 
splitting of the sternum. The principle fol-
lowed is to dissect the aorta for crossclamping 
at a level that will allow intraaortic infusion of 
cold fluids, which will pass into the organs to 
be removed. If the liver is to be one of these 
organs, dissection of the liver hilum is carried 
out, after which the liver can be infused 
through both the aorta and portal vein (Fig 
10). The kidneys are also cooled by the aortic 
perfusion. With minor modifications, the 
heart can also be excised. 
This procurement technique requires 
"brain death" conditions and stable cardio-
vascular function. An alternative with which 
we have had recent experience can be done 
swiftly, and in donors who have had cardiac 
arrest.42 With this so-called fast method, a 
crossclamp is placed on the aorta near the 
diaphragm and cold solutions (usually the 
high-potassium high-magnesium concentra-
tion Collin's solution) are infused rapidly. 
Blood enters the liver through the normal 
celiac axis route but also through the portal 
vein after passing through the splanchnic cap-
illary bed. The portal venous blood quickly 
becomes almost red cell free. 
The cold ischemia limit permissible for a 
human liver graft has been set arbitrarily at 
ten hours, but great efforts are made to work 
within a five- or six-hour time frame. One of 
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the most urgent needs in liver transplantation 
is the development of better methods of pres-
ervation. Any technique that would allow safe 
preservation of livers for the better part of a 
day would revolutionize the field overnight. 
SUMMARY 
Liver transplantation has become an 
accepted service during the last five years. 
The introduction of cyclosporine-steroid ther-
apy has been the most important factor in 
making this possible. Improvements in surgi-
cal technique, including perfection of intra-
operative venovenous bypasses and the stan-
dardization of biliary tract reconstruction 
have also contributed. Tissue typing and 
matching have played no role in improving the 
results of liver transplantation. With the dem-
onstration that preformed antibody states are 
irrelevant, even avoidance of positive cross-
matches caused by cytotoxic antibodies and 
observance of ABO blood group barriers have 
become unnecessary if the recipient's needs 
are great. The nature of the underlying 
hepatic disease has not profoundly influenced 
the results, with the exceptions of malignancy 
and cirrhosis. Retransplantation has played 
an important role in improving survival. The 
development of better methods of preservation 
that will allow the recipient operations to be 
done in a more leisurely manner and at more 
convenient times is the most pressing need for 
further application of liver transplantation at 
a national and international level. 
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